The utility of tumour necrosis factor blockade in orphan diseases

Annals of the Rheumatic Diseases

Volumn 63, Issue SUPPL. 2, 2004, Pages

  Keystone, E C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN D; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; METHOTREXATE; PREDNISONE; RIBAVIRIN; TUMOR NECROSIS FACTOR;

AMYLOIDOSIS; BEHCET DISEASE; CHRONIC HEPATITIS; CHURG STRAUSS SYNDROME; CONFERENCE PAPER; DEATH; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; GIANT CELL ARTERITIS; GRAFT VERSUS HOST REACTION; HEPATITIS C; HUMAN; HYPERIMMUNOGLOBULINEMIA; INFECTION; INTERVERTEBRAL DISK DISEASE; MUCOUS MEMBRANE PEMPHIGOID; MYELODYSPLASTIC SYNDROME; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS; POLYMYOSITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RELAPSING POLYCHONDRITIS; REMISSION; RETICULOHISTIOCYTOSIS; SAPHO SYNDROME; SARCOIDOSIS; SJOEGREN SYNDROME; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOGLOBULIN G; RARE DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOIDOSIS; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 7044251770     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.028498     Document Type: Conference Paper

References (65)

1. Fox RI, Kong HI, Ando D, Abrams J, Pisa E, Cytohine M. RNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994;152:5532-9.
2. Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmstrom M, Konttimen YT. Tumor necrosis factor α and receptors for it in labial salivary glands in Sjogren's syndrome. Clin Exp Rheumatol 2001;19:131-7.
3. Cauli A, Yanni G, Pitzalis C, Challacombe S, Panayi GS. Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjögren's syndrome and chronic sialoadenitis. Ann Rheum Dis 1994;54:209-15.
4. Sun D, Emmert-Buch MR, Fax PC. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjogrens syndrome. Autoimmunity 1998;28:125-37.
5. Azuma M, Motegi K, Aota K, Hayashi Y, Sato M. Role of cytokines in the destruction of acinar structure in Sjogrens syndrome salivary glands. Lab Invest 1997;77:269-80.
6. Moser RB, Scheiffenbaum B, Groscurth P, Fehr J. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989;83:444-55.
7. Tornwald J, Fox H, Edwards C, Fox RI. Treatment with pegylated recombinant methionyl human soluble tumor necrosis-factor with type 1 receptor (PEGSTNF-R1) prevents development of Sjogrens syndrome and diabetes in the NOD mouse model. Arthritis Rheum 1999;42(suppl 9):S403.
8. Steinfeld SD, Demols P, Salmon I, Kiss R, Appleboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
9. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Huchulla E, et al. lnefficacy of infiximab in primary Sjogren's syndrome: results of the randomized controlled trial of remicade in primary Sjogren's (TRIPPS). Arthritis Rheum 2004;50:1270-6.
10. Zandbelt M, de Wilde P, Van Damme P, Hoyng CB, van de Putte LB, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31:96-101.
11. Hengstman G, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LBA, et al. Successful treatment of dermatomyositis with anti-tumor necrosis factor α. Preliminary observations. Eur Neurol 2003;50:10-15.
12. Saadeyh C. Etanercept is effective in the treatment of palymyositis/dermatomyositis which is refractory to conventional therapy. Arthritis Rheum 2000;43:S193.
13. Labioche E, Liozon B, Weschler B, Loustand-Ratti V, Soria P, Vidal E. Refractory palymyositis responding to infliximab: extensive follow up. Rheumatology 2004;43:531-2.
14. Nzeussseu A, Durez P, Houssiau F, et al. Successful use of infiximab in a case of refractory juvenile dermatomyositis. Arthritis Rheum 2001;44:590.
15. Miller M, Mendez E, Klein-Gitelman M, Pachman L. Use of etanercept in juvenile dermatomyositis. Arthritis Rheum 2002;46:MO766.
16. Ludviksson B, Sneller, Chua K, Talar-Williams C, Langford C, Ehrhardt R, et al. Active Wegener's granulomatosis is associated with HLA-DR4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 1998;160:3602-9.
17. Noronha I, Kruger C, Andrassy K, Ritz E, Waldherr R. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 1993;43:682-92.
18. Nassonov E, Samsonov M, Tilz G, Beketova T, Semenkova E, Baranov A, et al. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol 1997;24:666-70.
19. Bedoos NM, Uhfelder ML, Hellmann DB, Crook S, Hoffman GS. Etanercept combined with conventional treatment in WG: A six month open-label trial to evaluate safety. Arthritis Rheum 2001;41:1149-54.
20. Lamprecht P, Voswinkel J, Lilenthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF alpha blockade with infliximab refractory Wegener's granulomatosis. Rheumatology 2002;11:1303-7.
21. Booth AD, Jefferson HS, Ayliffe W, Andrews PA, Jayne DR, et al. Safety and efficacy of TNF alpha blockade in relapsing vasculitis. Ann Rheum Dis 2002;61:559.
22. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Systemic vasculitides: an open label pilot study on 10 patients. Rheumatology 2002;41:1126-32.
23. Gause AM, Arbach O, Reinhold-Keller E, Lamprecht P, Voswinkel J, Gross WL, et al. Induction of remission with infliximab in active generalized Wegener's granulomatosis in effective but complicated by severe infections. Arthritis Rheum 48:S208, abstract 450.
24. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
25. Gul A. Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001;19(suppl 24):S6-S12.
26. Turban B, Gallasti H, Erdi G, Gurler A, Michel BA, Billliger PM. Systemic levers of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32.
27. Evereklioglu C, Er W, Turkoz Y, Cekmen M. Serum levels of TNFα, SIL-2R, IL-6 and IL-8 are increased and associated elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002;11:87-93.
28. Santa Lacoma M, Martin C, Gallardo Galero JM, Collantes-Estevez E. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthal Res 2001;33:251-5.
29. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6.
30. Saulsburg FT, Mann JA. Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 2003;49:599-600.
31. Hassard PV, Binder SW, Nelson V, Vasiliauskas FA. Anti-tumor necrosis factor monoclonal antibody therapy far gastrointestinal Behcet's disease: a case report. Gastroenterology 2001;120:993.
32. Licata G, Pinto A, Tuttolomondo A, Banca A, Ciccia F, Ferrante A, et al. Antitumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis 2003;62:280-1.
33. Rozenbaum M, Rosner I, Portnoy E. Remission of Behcet's syndrome with TNF alpha blocking treatment. Ann Rheum Dis 2002;61:283-4.
34. Melikogllu M, Fresko I, Mat C, Yurkdakul S, Hamuryvdam V, Yazici H. Etanercept is beneficial in controlling the mucocutaneous lesions of Behcet's syndrome. Arthritis Rheum 2002;46: abstract 400.
35. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(suppl 2):ii51-ii53.
36. Joesph A, Raj D, Dua HS, Powell PT, Lawson PC, Powell RJ, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-53.
37. Suhler E, Smith J, Kurz D, Lover AK, Pickard TD, Rosenbaum JT. A prospective trial of infliximab therapy from patients with refractory uveitis: preliminary results. Arthritis Rheum 2003;48:S422.
38. Gulli S, Arrigo C, Bocchino L, Morgan TE, Sangari D, Castagna E, et al. Remission or Behcet's desease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003;4:19.
39. Field M, Cook A, Gallagher G. Immunolocalisation of tumor necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997;17:113-18.
40. Cantini F, Niccoli L, Salvarani C, Pachula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001;44:2933-5.
41. Andonopoulos AP, Meimans N, Daoussis D, Bounas A, Giannopaulous G. Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:1116.
42. Tan A, Holdsworth J, Pease C, Emery P, McGonagal D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2000;62:373-4.
43. Salvarani C, Cantini F, Niccoli L, Catanosa MG, Marcchioni P, Pulsatelli P, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheum 2003;30:760-3.
44. Hoffman G, Merkel P, Brassington R, Lenschow D, Kissin E, Liang G. Utility of anti-TNF therapy in Takayasu's arteritis. Arthritis Rheum 2003;48:5442.
45. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss Syndrome (CSS) by TNF alpha blockade. Immunobiology 2002;206:496-501.
46. Whitney-Mahoney KJ, Parker S, Benseler S, Laxer R. The role of infliximab in a pediatric patient with polyarteritis nodosa. Arthritis Rheum 2003;48: abstract 455.
47. Kunkel SL, Chensue SW, Strieter RM, Lynch JP, Remick DG. Cellular and molecular aspects of granulomatous inflammation. Am J Resp Cell Mol Biol 1989;1:1439-47.
48. Ziegenhagen MW, Benner G, Zissel. Sarcoidosis TNF-alpha release from alveolar macrophages and serum level of IL-2R are prognostic markers. Am J Resp Crit Care Med 1997;156:1586-98.
49. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic A, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003;124:177-85.
50. Baughman RP, Bradley DA, Raymond IO, Lower EE, Kerr MA, Winget DB, et al. Double blind randomized trial of a tumor necrosis factor receptor antagonist (Etanercept) for treatment of chronic ocular sarcoidosis. Presented at the American Thoracic Society 2002; Abstract 917.
51. Ulbricht DU, Stoll M, Bierwkith J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 2003;44:3542-3.
52. Baughman RP, Iannuzzi M. Tumor necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 2003;17:425-31.
53. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest 2003;124:2028-31.
54. Baughmann RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-18.
55. Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother 2003;37:577-81.
56. O'Connor TM, Shanahan F, Bredin CP. Infliximab therapy for complicated sarcoidosis. Ann Intern Med 2002;137:296-7.
57. Cook MC. Infliximab therapy for complicated sarcoidosis. Ann Intern Med 2002;137:296-7.
58. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha treatment. Ann Intern Med 2001;135:27-31.
59. Baughmann RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4. Erraratum in Sarcoidosis Vasc Diffuse Lung Dis 2001;18:310.
60. Baughmann RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4. Erraratum in Sarcoidosis Vasc Diffuse Lung Dis 2001;18:310.
61. Zein NN, Etanercept Study Group. A phase II randomized double blind, placebo controlled study of Tumor Necrosis Factor antagonist (Etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naive patients with chronic hepatitis. Presented at the American Association for Study of Liver Diseases, 2002, Boston. (Abstract 101808).
62. Oniankitan O, Dusoux C, Challine D, Mallat A, Chevelier X, Pawlotsky Metal J. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B and C. J Rheumatol 2004;31:107-9.
63. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B versus treated for an adult onset stills disease. J Rheumatol 2003;30:1624-5.
64. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini P. Persistent efficacy of tumor necrosis factor alpha blockade therapy in SAPHO. Arthritis Rheum 2003;48:1467-8.
65. Wagner AD, Andersen J, Jendro MC, Hulsemann J, Zeidler H. Sustained response to tumor necrosis factor alpha blockade agents in two patients with SAPHO syndrome. Arthritis Rheum 2002;46:1965-8.